CN103977088B - A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent - Google Patents
A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent Download PDFInfo
- Publication number
- CN103977088B CN103977088B CN201410202807.3A CN201410202807A CN103977088B CN 103977088 B CN103977088 B CN 103977088B CN 201410202807 A CN201410202807 A CN 201410202807A CN 103977088 B CN103977088 B CN 103977088B
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- paeoniae rubra
- drug
- antibacterial agent
- compound medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent, be made up of the raw material of following weight portion: fluoroquinolone antibacterial agent 3 30 parts, Radix Paeoniae Rubra 5 200 parts；Described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.The present invention can the reverse bacterial drug resistance to antimicrobial drug, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the addition of 0.1 7g principal agent/kg feedstuff and feed, drug cost and drug residue can be greatly reduced, create higher economic benefit for raiser, also ensure that food safety simultaneously.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, particularly relate to a kind of antibacterial containing Radix Paeoniae Rubra and fluoroquinolones
The poultry compound medicine of medicine.
Background technology
Escherichia coli are common conditioned pathogens, are also a kind of diseases often sent out, and it primary can cause chicken acute sepsis, abdomen
The multiple location severe infections such as film inflammation, hepatitis, pneumonia, enteritis, also can secondary or mixed send out in virosis, cause huge to aquaculture
Economic loss.Amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/
The beta-lactam nucleus class antibiotic such as sulbactam are the conventional important drugs preventing and treating this disease, along with cultivation scale intensive degree more comes
Bigger, medication is more and more spread unchecked, and its Resistant strain is the most, and the report about Drug Resistance of E. coli is the most more.Research card
Real, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-
Spectrum β-lactamase, ESBLs), this enzyme can hydrolyze beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose
Lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and right
Aminoglycoside, quinolones and sulfonamides are crossing drug resistant, only to carbapenems, a mould alkenes medicaments insensitive.Many literary compositions
Offer it has been reported that colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to more pay close attention to.Inventor
The detection of food animal source pathogenic bacterium ESBLs, extraction, enzyme are carried out recently to the percent hydrolysis of antibiotic and sulbactam, his azoles bar
Smooth and Chinese medicine the enzyme protection effect that presses down etc. is studied, and drug sensitive test colibacillary to part ESBLs shows, its multidrug resistant rate
Apparently higher than non-ESBLs bacterial strain.It addition, result also shows to produce ESBLs bacterial strain not only to third generation cephalosporins such as ceftiofurs
Serious drug resistance, and also antimicrobial drug drug resistance multiple to fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in seriously
Multidrug resistant.Inventor is separated to resistance to fosfomycin in producing ESBLs bacterial strain and produces the escherichia coli of fosA3 drug resistant gene, more
The strong drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and poultry are dead
Rate increases, and brings bigger economic loss to production, and increases poultry drug residue risk.Therefore, actual production needs one badly
Kind to regardless of whether the escherichia coli of drug resistance can have a medicine of preferable therapeutical effect, and can shorten and treat the course for the treatment of, minimizing mortality rate,
Reduce economic loss and reduce drug residue, creating higher economic benefit for raiser, also ensure that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent,
It can kill antibacterial quickly, overcome weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, consumption is big, residual is high and
The defect that cost is high, it is to avoid simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For solving above technical problem, the present invention by the following technical solutions: a kind of containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent
Poultry compound medicine, is made up of the raw material of following weight portion: fluoroquinolone antibacterial agent 3-30 part, Radix Paeoniae Rubra 5-200 part.
Described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.
Further, described compound medicine is made up of the raw material of following weight portion: ciprofloxacin 3-20 part and Radix Paeoniae Rubra 40-180
Part, or norfloxacin 3-25 part and Radix Paeoniae Rubra 30-190 part.
Described compound medicine is prepared as powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Radix Paeoniae Rubra pulverized 60 mesh sieves, then mixes, by often with the antimicrobial drug of powder
Rule method is prepared as powder, tablet, oral liquid or granule.
The drug resistance problems existed for current poultry coli-infection, inventor utilizes Lactiflora to form compound recipe with antimicrobial drug
Medicine.Research proves, after adding Radix Paeoniae Rubra, it is possible to the reverse bacterial drug resistance to antimicrobial drug, thus improves antimicrobial drug in antimicrobial drug
Therapeutic effect.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, according to 0.1-7g principal agent
The addition of/kg feedstuff adds in animal and fowl fodder and feeds, and drug cost and drug residue can be greatly reduced, for raiser
Create higher economic benefit, also ensure that food safety simultaneously.
Detailed description of the invention
One, the Radix Paeoniae Rubra drug resistance inversion Effect study to antimicrobial drug
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger owing to producing the escherichia coli of ESBLs drug resistant gene
Drug resistance, causes antimicrobial drug not show preferable therapeutic effect in the case of normal using dosage.
In order to verify the Radix Paeoniae Rubra drug resistance inversion effect to antimicrobial drug, 96 orifice plates use microtest tube doubling dilution, first measures
Antimicrobial drug to produce the minimal inhibitory concentration of e. coli strains of ESBLs and fosA3 drug resistant gene and Radix Paeoniae Rubra to produce ESBLs and
The subinhibitory concentration of fosA3 drug resistant gene e. coli strains, the Radix Paeoniae Rubra adding subinhibitory concentration the most in the medium reuses
Microtest tube doubling dilution cultivates the minimal inhibitory concentration measuring antimicrobial drug；Utilize continuous passage method added with same sub-antibacterial dense
The culture medium of degree Radix Paeoniae Rubra and same concentration antimicrobial drug carries out Secondary Culture to product ESBLs and fosA3 drug resistant gene e. coli strains,
Until the antimicrobial drug minimal inhibitory concentration observed with pass on before compared with diminish more than 4 times, can be judged as that Radix Paeoniae Rubra is to antibacterial medical instrument
There is drug resistance inversion effect.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra passes on and causes the change producing ESBLs and fosA3 escherichia coli Western medicine MIC
(μg/mL)。
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, i.e. can determine whether it is Radix Paeoniae Rubra
To producing ESBLs and fosA3 drug resistant gene escherichia coli, there is drug resistance inversion effect.
Two, the application example of compound medicine of the present invention
Prepare embodiment 1-embodiment 8 according to table 2 formula and following methods: after Radix Paeoniae Rubra was pulverized 60 mesh sieves, based on former
Material, then mix during ratio puts into blender by weight with the antimicrobial drug of powder, according to a conventional method, compound medicine is prepared as
Formulation products.
The formula of table 2 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Radix Paeoniae Rubra | Dosage form |
| Embodiment 1 | Ciprofloxacin 3g | 120g | Tablet |
| Embodiment 2 | Ciprofloxacin 10g | 90g | Powder |
| Embodiment 3 | Ciprofloxacin 14g | 40g | Oral liquid |
| Embodiment 4 | Ciprofloxacin 20g | 180g | Granule |
| Embodiment 5 | Norfloxacin 13g | 190g | Tablet |
| Embodiment 6 | Norfloxacin 15g | 85g | Powder |
| Embodiment 7 | Norfloxacin 3g | 5g | Oral liquid |
| Embodiment 8 | Norfloxacin 25g | 30g | Granule |
Above-described embodiment is obtained compound medicine product and has carried out following experiment by inventor:
1, the compound medicine product of the embodiment 1-4 gained efficacy experiment to chicken escherichia coil disease
Clinical symptoms: Guigang, Guangxi chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and bag pericardium occurs
Liver pathological change, typical bacillus coli feature.
Laboratory diagnosis: take pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, it is seen that red Gram-negative bar
Bacterium；Tentatively it is judged as bacillus coli.Being cultivated by escherichia coli, biochemical test differentiates, it is judged that chicken infects for large intestine bar
Bacterial diseases, PCR expands, it was demonstrated that produce the ESBLs drug resistant gene having TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, first group by embodiment 1 according to the interpolation of 3.5g/kg feedstuff
Amount be administered, second group with embodiment 2 according to 1g/kg feedstuff addition be administered, the 3rd group by embodiment 3 according to 0.4g/kg
The addition of feedstuff is administered, and the 4th group is administered according to the addition of 1g/kg feedstuff by embodiment 4；Use ciprofloxacin powder for 5th group
Agent is administered according to the addition of 0.1g/kg feedstuff, and the 6th group is administered according to the addition of 4g/kg feedstuff with the thick powder of Radix Paeoniae Rubra；With
Upper six groups of therapeutic regimens the most persistently use 5 days.
Staining effect: after chicken group's medication of first group to the 4th group, sick chicken feed intake rises, and dead chicken no longer occurs, is continuing with
3 days, chicken group be almost recovered；After chicken group's medication of the 5th group 2 days, chicken group's majority is the most unhealthy, still has indivedual chicken death, continues
Continuous use 3 days, chicken death phenomenon is still without being effectively controlled；After chicken group's medication of the 6th group 2 days, chicken group is the biggest
Remarkable improvement, is continuing with 3 days, and chicken death phenomenon is still without being effectively controlled.Visible, the compound medicine containing Radix Paeoniae Rubra is treated
Effect is better than folk prescription.
2, the efficacy experiment that the meat-type duck of 20 ages in days is suffered from diarrhoea by the compound medicine product of embodiment 5-8 gained
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has the most indigested in feces
Feedstuff.Duck group material feeding but the longest, indivedual serious ducks of suffering from diarrhoea gradually occur that foot is soft slowly dead.
Cuing open inspection pathological changes: the duck that dies of illness dehydration ratio is more serious, indivedual ducks are the biggest, duck liver enlargement, hyperemia, the liver of part duck
On have a white films, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, and first group is administered according to the addition of 3g/kg feedstuff by embodiment 5,
Second group with embodiment 6 according to 1.3g/kg feedstuff addition be administered, the 3rd group by embodiment 7 according to 0.5g/kg feedstuff
Addition is administered, and the 4th group is administered according to the addition of 0.45g/kg feedstuff by embodiment 8；Press with norfloxacin powder for 5th group
Addition according to 0.2g/kg feedstuff is administered, and the 6th group is administered according to the addition of 4g/kg feedstuff with the thick powder of Radix Paeoniae Rubra；Above six
Group therapeutic regimen the most persistently uses 5 days.
Using effect is fed back: after first group to the 4th group medication 2 days, sick duck no longer draws watery stools, formed stools, no longer goes out
Now dead duck, is continuing with 3 days, and duck group be almost recovered；After 5th group of medication 2 days, duck group's DeGrain, the most still draws
Watery stools, containing indigested feedstuff, is continuing with 3 days, somewhat takes a turn for the better, but the best thorough, dilute watery stools
Or occur, raiser cannot drug withdrawal, the compound medicine of embodiment 6 gained have to be used instead, be continuing with 2 days, the most substantially fully recover from an illness
More, re-using 1 day, feces all transfers to normally；After 6th group of medication 2 days, duck does not has the biggest remarkable improvement, continues to make
With 3 days, the duck phenomena of mortality were still without being effectively controlled.Visible, the curative effect that duck is suffered from diarrhoea by compound medicine containing Radix Paeoniae Rubra is better than
Folk prescription.
Claims (3)
1. Radix Paeoniae Rubra and fluoroquinolone antibacterial agent are combined preparation answering in terms for the treatment of poultry coli-infection disease preparation
With, it is characterised in that in described preparation, the weight ratio of Radix Paeoniae Rubra and fluoroquinolone antibacterial agent is: fluoroquinolones resists
Bacterium medicine 3-30 part, Radix Paeoniae Rubra 5-200 part；Described fluoroquinolone antibacterial agent is ciprofloxacin or levofloxacin.
Application the most according to claim 1, it is characterised in that in described preparation, ciprofloxacin and the weight portion of Radix Paeoniae Rubra
Ratio is: ciprofloxacin 3-20 part, Radix Paeoniae Rubra 40-180 part.
Application the most according to claim 1 and 2, it is characterised in that described preparation be powder, tablet, oral liquid or
Granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202807.3A CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202807.3A CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103977088A CN103977088A (en) | 2014-08-13 |
| CN103977088B true CN103977088B (en) | 2017-01-04 |
Family
ID=51269415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410202807.3A Active CN103977088B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103977088B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306645A (en) * | 2014-09-30 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Injection with antibacterial and anti-inflammatory effects for livestock and poultry and preparation method thereof |
| CN106166173A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and norfloxacin |
| CN106109549A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and norfloxacin |
| CN106176942A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and norfloxacin |
| CN106265920A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and norfloxacin |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396485A (en) * | 2007-09-29 | 2009-04-01 | 张勇 | Traditional Chinese medicine formulation for treating sucking pig yellow and white scours |
| CN101554365A (en) * | 2008-04-11 | 2009-10-14 | 天津生机集团股份有限公司 | Norfloxacin transdermal agent for preventing and curing yellow and white scour piglet and preparation method thereof |
| CN101926846A (en) * | 2010-09-01 | 2010-12-29 | 河南新正好生物工程有限公司 | Medicinal composition for treating pullorum disease and preparation method thereof |
| CN101953882A (en) * | 2010-10-15 | 2011-01-26 | 郑州后羿制药有限公司 | Compound microcapsule for treating bacterial disease of livestock and poultry and preparation method thereof |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103301463A (en) * | 2013-06-13 | 2013-09-18 | 广西南宁市桃源兽药厂 | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases |
| CN103690952A (en) * | 2013-11-27 | 2014-04-02 | 广西大学 | Compound drug for treating livestock and poultry escherichia coli infected diseases |
-
2014
- 2014-05-14 CN CN201410202807.3A patent/CN103977088B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396485A (en) * | 2007-09-29 | 2009-04-01 | 张勇 | Traditional Chinese medicine formulation for treating sucking pig yellow and white scours |
| CN101554365A (en) * | 2008-04-11 | 2009-10-14 | 天津生机集团股份有限公司 | Norfloxacin transdermal agent for preventing and curing yellow and white scour piglet and preparation method thereof |
| CN101926846A (en) * | 2010-09-01 | 2010-12-29 | 河南新正好生物工程有限公司 | Medicinal composition for treating pullorum disease and preparation method thereof |
| CN101953882A (en) * | 2010-10-15 | 2011-01-26 | 郑州后羿制药有限公司 | Compound microcapsule for treating bacterial disease of livestock and poultry and preparation method thereof |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
| CN103127508A (en) * | 2013-03-18 | 2013-06-05 | 广西大学 | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry |
| CN103301463A (en) * | 2013-06-13 | 2013-09-18 | 广西南宁市桃源兽药厂 | Compound composition containing plumbago zeylanica for treating livestock and poultry escherichia coli infection diseases |
| CN103690952A (en) * | 2013-11-27 | 2014-04-02 | 广西大学 | Compound drug for treating livestock and poultry escherichia coli infected diseases |
Non-Patent Citations (1)
| Title |
|---|
| 赤芍提取物体外抑菌活性的研究;张芳等;《徐州医学院学报》;20061231;第26卷(第05期);418－420 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103977088A (en) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728A (en) | Acalypha australis L. and beta-lactam antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103989730A (en) | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543B (en) | Utilize the method for Herba Andrographis and colistin treatment poultry coli-infection disease | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN103948912B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and colistin | |
| CN103933085B (en) | The application of Herba Andrographitis and phosphonomycin in the compound medicine for preparing treatment livestock and poultry coli-infection disease | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN104435011A (en) | Compound medicine containing herba pteridis multifidae and beta-lactam antibiotics drugs for livestock and poultry | |
| CN103933109A (en) | Method for treating animal escherichia coli infected diseases | |
| CN105726588A (en) | Compound medicine containing radix helicteris and sulfamonomethoxine sodium for livestock and poultry | |
| CN105663181A (en) | Compound medicine containing narrowleaf screwtree roots and beta-lactam antimicrobial drugs and used for livestock | |
| CN104436161A (en) | Pteris multifida and colistin-containing compound drug for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |